What is Sift Bio?
Sift Bio operates at the intersection of artificial intelligence and cellular biology, specializing in the development of immunotherapy boosters designed to augment the efficacy of existing cancer treatments. By leveraging high-throughput cellular screening and advanced machine learning algorithms, the company identifies and optimizes candidates that enhance immune cell performance. This technological approach addresses critical gaps in current oncology protocols, aiming to improve patient outcomes through precision-engineered biological interventions. As a key player in the biotech sector, Sift Bio is effectively bridging the gap between computational discovery and clinical application.
How much funding has Sift Bio raised?
Sift Bio has raised a total of $3.7M across 1 funding round:
Angel/Pre-Seed
$3.7M
Angel/Pre-Seed (2026): $3.7M with participation from Freeflow Ventures, Lifespan Vision Ventures, and Eisai Innovation, Inc.
Key Investors in Sift Bio
Freeflow Ventures
An early-stage venture firm focused on deep tech solutions that address human and planetary health, leveraging proprietary IP and AI technologies.
Lifespan Vision Ventures
A specialized investment firm dedicated to financing diagnostics and therapeutics aimed at longevity, aging reversal, and extending the human healthspan.
Eisai Innovation, Inc.
The corporate venture arm of a global research-based pharmaceutical company, focusing on innovative solutions in oncology and neurology to address unmet medical needs.
What's next for Sift Bio?
With this major enterprise-level funding, Sift Bio is poised to transition from early-stage discovery into more robust clinical validation phases. The strategic focus will likely center on scaling its high-throughput screening infrastructure and deepening its collaborative efforts with global pharmaceutical partners. By utilizing the recent capital to refine its AI-driven candidate design, the company aims to shorten the development cycle for next-generation immunotherapy boosters. Future growth will be defined by the firm's ability to translate its computational insights into tangible therapeutic assets that meet the high unmet medical needs within the oncology market.
See full Sift Bio company page
